IKT

$0.00

(

+0.00%

)
Quote details

stock

Inhibikase Therapeutics Inc

NASDAQ | IKT

1.47

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 31, 2025)

$108.79M

Market Cap

-

P/E Ratio

-0.04

EPS

$4.20

52 Week High

$1.41

52 Week Low

HEALTHCARE

Sector

IKT Chart

Recent Chart
Price Action

IKT Technicals

Tags:

IKT Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$26K
Total Revenue $0
Cost Of Revenue $26K
Costof Goods And Services Sold $26K
Operating Income -$29M
Selling General And Administrative $11M
Research And Development $17M
Operating Expenses $29M
Investment Income Net -
Net Interest Income $1.1M
Interest Income $1.1M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $26K
Income Before Tax -$28M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$28M
Comprehensive Income Net Of Tax -
Ebit -$28M
Ebitda -$27M
Net Income -$28M

Revenue & Profitability

Earnings Performance

IKT Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $99M
Total Current Assets $98M
Cash And Cash Equivalents At Carrying Value $56M
Cash And Short Term Investments $56M
Inventory -
Current Net Receivables -
Total Non Current Assets $149K
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $41M
Other Current Assets $908K
Other Non Current Assets -
Total Liabilities $3.7M
Total Current Liabilities $3.7M
Current Accounts Payable $943K
Deferred Revenue -
Current Debt -
Short Term Debt $221K
Total Non Current Liabilities $0
Capital Lease Obligations $111K
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $111K
Other Current Liabilities $2.6M
Other Non Current Liabilities -
Total Shareholder Equity $95M
Treasury Stock -
Retained Earnings -$94M
Common Stock $69K
Common Stock Shares Outstanding $24M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$19M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $26K
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$37M
Cashflow From Financing $103M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$28M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$26K
Total Revenue $0
Cost Of Revenue $26K
Costof Goods And Services Sold $26K
Operating Income -$29M
Selling General And Administrative $11M
Research And Development $17M
Operating Expenses $29M
Investment Income Net -
Net Interest Income $1.1M
Interest Income $1.1M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $26K
Income Before Tax -$28M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$28M
Comprehensive Income Net Of Tax -
Ebit -$28M
Ebitda -$27M
Net Income -$28M

IKT News

IKT Profile

Inhibikase Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Atlanta, Georgia, dedicated to advancing innovative therapies for Parkinson's disease (PD) and related neurodegenerative disorders. The company employs a novel dual-targeting approach that addresses both central and peripheral mechanisms of neurodegeneration, aiming to tackle significant unmet medical needs within the PD patient population. With a robust pipeline of therapeutics currently in clinical development, Inhibikase is well-positioned to drive meaningful advancements in PD treatment, ultimately striving to improve the quality of life for patients coping with these challenging conditions.

EPWK
+29.15%
$0.08
VHAI
0.00%
$0.00
YDKG
+21.59%
$0.05
HKD
+74.55%
$2.95
WTO
+6.92%
$0.04
MSAI
+18.18%
$1.56
INTS
-44.68%
$0.73
NVDA
-0.19%
$202.49
AMZN
+9.58%
$244.22
BENF
+48.24%
$0.82
PFE
+1.48%
$24.65
GETY
-6.21%
$1.88
IXHL
+17.77%
$0.40
ASST
+9.91%
$1.33
DVLT
-19.44%
$2.02
ONDS
+2.38%
$6.44
BYND
+0.30%
$1.65
BURU
+0.05%
$0.33
BTG
-10.16%
$4.37
NOK
-3.15%
$6.90
PLUG
+1.50%
$2.69
T
+0.20%
$24.73
CTM
+14.07%
$1.17
DNN
-1.39%
$3.17
JZXN
+18.07%
$0.32
AAPL
-0.37%
$270.37
QS
+16.78%
$18.44
TSLA
+3.74%
$456.56
F
-1.35%
$13.06
INTC
-0.42%
$39.99
BITF
-2.21%
$3.97
AZI
+3.38%
$0.09
RIG
-1.91%
$3.83
NWL
-27.96%
$3.40
AXDX
-61.36%
$0.03
RGTI
+4.11%
$44.27
SOFI
+2.23%
$29.68
GPUS
-7.59%
$0.40
ADTX
-12.64%
$0.05
TGE
-51.29%
$0.81
LAZR
-45.02%
$1.15
CJET
-9.39%
$0.04
META
-2.71%
$648.35
PLTR
+3.04%
$200.47
VZ
+2.00%
$39.74
CAN
+15.32%
$1.43
ADAP
-15.14%
$0.05
NIO
+3.49%
$7.25
CMG
-2.59%
$31.68
LUMN
-0.67%
$10.27
WULF
+4.58%
$15.50
NLSP
+2.97%
$0.76
MNOV
+39.49%
$1.66
KVUE
+0.94%
$14.37
VALE
+1.76%
$12.10
RANI
+51.72%
$2.20
SNAP
+2.56%
$7.79
CERO
-94.68%
$0.09
CCL
+1.72%
$28.82
AAL
+2.73%
$13.13
RIVN
+4.46%
$13.57
QUBT
+11.62%
$16.71
CIFR
-2.20%
$18.64
WBD
+3.83%
$22.45
JOBY
+4.80%
$17.34
RXRX
-2.30%
$5.52
GRAB
+0.50%
$6.01
CLF
+1.34%
$12.42
TLRY
+3.87%
$1.34
ACHR
-1.96%
$10.96
RMBL
+60.50%
$3.21
BAC
+0.82%
$53.47
GOOGL
-0.10%
$281.19
AMCR
+0.76%
$7.91
BTBT
-6.84%
$3.54
ADD
-25.47%
$0.05
ABEV
+0.65%
$2.31
QBTS
+2.63%
$37.06
METU
-22.78%
$34.04
ETHD
-10.42%
$3.78
BBD
-0.14%
$3.38
PFSA
-9.85%
$0.25
CABA
+46.15%
$3.61
SRM
+53.27%
$10.30
AMD
+0.50%
$256.12
MSFT
-1.51%
$517.80
HPE
+0.02%
$24.41
MARA
+2.87%
$18.27
LAES
+7.69%
$7.42
RIOT
-6.21%
$19.78
NAKA
+8.92%
$0.92
DFSC
+20.68%
$5.25
APLD
+2.09%
$34.65
KHC
+0.61%
$24.73
AGNC
-0.59%
$10.00
FI
+2.31%
$66.70
GOOG
-0.02%
$281.82
MRVL
+5.83%
$93.74
WLGS
-5.57%
$0.04
SOUN
+4.44%
$17.62
EPWK
+29.15%
$0.08
VHAI
0.00%
$0.00
YDKG
+21.59%
$0.05
HKD
+74.55%
$2.95
WTO
+6.92%
$0.04
MSAI
+18.18%
$1.56
INTS
-44.68%
$0.73
NVDA
-0.19%
$202.49
AMZN
+9.58%
$244.22
BENF
+48.24%
$0.82
PFE
+1.48%
$24.65
GETY
-6.21%
$1.88
IXHL
+17.77%
$0.40
ASST
+9.91%
$1.33
DVLT
-19.44%
$2.02
ONDS
+2.38%
$6.44
BYND
+0.30%
$1.65
BURU
+0.05%
$0.33
BTG
-10.16%
$4.37
NOK
-3.15%
$6.90
PLUG
+1.50%
$2.69
T
+0.20%
$24.73
CTM
+14.07%
$1.17
DNN
-1.39%
$3.17
JZXN
+18.07%
$0.32
AAPL
-0.37%
$270.37
QS
+16.78%
$18.44
TSLA
+3.74%
$456.56
F
-1.35%
$13.06
INTC
-0.42%
$39.99
BITF
-2.21%
$3.97
AZI
+3.38%
$0.09
RIG
-1.91%
$3.83
NWL
-27.96%
$3.40
AXDX
-61.36%
$0.03
RGTI
+4.11%
$44.27
SOFI
+2.23%
$29.68
GPUS
-7.59%
$0.40
ADTX
-12.64%
$0.05
TGE
-51.29%
$0.81
LAZR
-45.02%
$1.15
CJET
-9.39%
$0.04
META
-2.71%
$648.35
PLTR
+3.04%
$200.47
VZ
+2.00%
$39.74
CAN
+15.32%
$1.43
ADAP
-15.14%
$0.05
NIO
+3.49%
$7.25
CMG
-2.59%
$31.68
LUMN
-0.67%
$10.27
WULF
+4.58%
$15.50
NLSP
+2.97%
$0.76
MNOV
+39.49%
$1.66
KVUE
+0.94%
$14.37
VALE
+1.76%
$12.10
RANI
+51.72%
$2.20
SNAP
+2.56%
$7.79
CERO
-94.68%
$0.09
CCL
+1.72%
$28.82
AAL
+2.73%
$13.13
RIVN
+4.46%
$13.57
QUBT
+11.62%
$16.71
CIFR
-2.20%
$18.64
WBD
+3.83%
$22.45
JOBY
+4.80%
$17.34
RXRX
-2.30%
$5.52
GRAB
+0.50%
$6.01
CLF
+1.34%
$12.42
TLRY
+3.87%
$1.34
ACHR
-1.96%
$10.96
RMBL
+60.50%
$3.21
BAC
+0.82%
$53.47
GOOGL
-0.10%
$281.19
AMCR
+0.76%
$7.91
BTBT
-6.84%
$3.54
ADD
-25.47%
$0.05
ABEV
+0.65%
$2.31
QBTS
+2.63%
$37.06
METU
-22.78%
$34.04
ETHD
-10.42%
$3.78
BBD
-0.14%
$3.38
PFSA
-9.85%
$0.25
CABA
+46.15%
$3.61
SRM
+53.27%
$10.30
AMD
+0.50%
$256.12
MSFT
-1.51%
$517.80
HPE
+0.02%
$24.41
MARA
+2.87%
$18.27
LAES
+7.69%
$7.42
RIOT
-6.21%
$19.78
NAKA
+8.92%
$0.92
DFSC
+20.68%
$5.25
APLD
+2.09%
$34.65
KHC
+0.61%
$24.73
AGNC
-0.59%
$10.00
FI
+2.31%
$66.70
GOOG
-0.02%
$281.82
MRVL
+5.83%
$93.74
WLGS
-5.57%
$0.04
SOUN
+4.44%
$17.62

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.